Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 6/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.44 |
| ▸ | RPA1 | P27694 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15167854 | 0.92 | L3MBTL1 (0.64) | L3MBTL1SCN9ANPY5RMALT1NFKB1 | |
| SCHEMBL20788373 | 0.88 | SMN1; SMN2 (0.57) | L3MBTL1NPY5RMALT1NFKB1NFKB2 | |
| SCHEMBL20788274 | 0.85 | SCN9A (0.55) | SCN9ANPY5RHPGD | |
| SCHEMBL20788268 | 0.84 | CYP17A1 (0.50) | L3MBTL1SCN9A | |
| SCHEMBL20788403 | 0.84 | CHRNA7 (0.56) | TP53HPGDCHRNA7 | |
| SCHEMBL20788407 | 0.83 | L3MBTL1 (0.54) | L3MBTL1SCN9ANPY5RMALT1SMN1; SMN2 | |
| SCHEMBL20788386 | 0.83 | SCN9A (0.45) | L3MBTL1SCN9A | |
| SCHEMBL20788432 | 0.83 | SCN9A (0.45) | L3MBTL1SCN9ATP53HPGDSMN1; SMN2 | |
| SCHEMBL20788211 | 0.81 | HRH3 (0.47) | L3MBTL1SCN9A | |
| SCHEMBL20788440 | 0.81 | HRH3 (0.44) | L3MBTL1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681883-B1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| CN-111094278-B | Diphenyl derivative and use thereof | 诺华股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-3681883-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2020-07-22 | — | — | EP | disclosed |
| CN-111094278-A | Diphenyl derivatives and their use | 诺华股份有限公司 | 2020-05-01 | — | — | CN | disclosed |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | NOVARTIS AG (CH) | 2020-04-28 | — | — | US | disclosed |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | NOVARTIS AG (CH) | 2020-04-28 | — | — | US | disclosed |
| WO-2019053090-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-03-21 | — | — | WO | disclosed |
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-03-14 | — | — | US | disclosed |
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | MYOF, NGF, MUSK | L3MBTL1 1366/4885SCN9A 2916/4885NPY5R 3243/4885 |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | MYOF, NGF, MUSK | L3MBTL1 1366/4885SCN9A 2916/4885NPY5R 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.